These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 37798397

  • 1. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM, Abdulmalik O, El-Say KM, Ghatge MS, Cyril-Olutayo M, Paredes S, Al-Awadh M, El-Araby ME, Safo MK.
    Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
    [Abstract] [Full Text] [Related]

  • 2. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM, Abdulmalik O, Ghatge MS, Muhammad YA, Paredes SD, El-Araby ME, Safo MK.
    Biomolecules; 2020 Nov 02; 10(11):. PubMed ID: 33147875
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA, Jefferson A, Chew-Martinez D, Matthews JS.
    Acc Chem Res; 2023 Jun 06; 56(11):1279-1286. PubMed ID: 36946781
    [Abstract] [Full Text] [Related]

  • 4. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG, Pagare PP, Ghatge MS, Safo RP, Gazi A, Chen Q, David T, Alabbas AB, Musayev FN, Venitz J, Zhang Y, Safo MK, Abdulmalik O.
    Mol Pharm; 2017 Oct 02; 14(10):3499-3511. PubMed ID: 28858508
    [Abstract] [Full Text] [Related]

  • 5. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK, Abdulmalik O, Danso-Danquah R, Burnett JC, Nokuri S, Joshi GS, Musayev FN, Asakura T, Abraham DJ.
    J Med Chem; 2004 Sep 09; 47(19):4665-76. PubMed ID: 15341482
    [Abstract] [Full Text] [Related]

  • 6. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O, Pagare PP, Huang B, Xu GG, Ghatge MS, Xu X, Chen Q, Anabaraonye N, Musayev FN, Omar AM, Venitz J, Zhang Y, Safo MK.
    Sci Rep; 2020 Nov 20; 10(1):20277. PubMed ID: 33219275
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK, Kato GJ.
    Hematol Oncol Clin North Am; 2014 Apr 20; 28(2):217-31. PubMed ID: 24589263
    [Abstract] [Full Text] [Related]

  • 8. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct 20; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 9. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP, Ghatge MS, Musayev FN, Deshpande TM, Chen Q, Braxton C, Kim S, Venitz J, Zhang Y, Abdulmalik O, Safo MK.
    Bioorg Med Chem; 2018 May 15; 26(9):2530-2538. PubMed ID: 29655608
    [Abstract] [Full Text] [Related]

  • 10. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.
    Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK.
    Expert Opin Ther Pat; 2022 Feb 15; 32(2):115-130. PubMed ID: 34657559
    [Abstract] [Full Text] [Related]

  • 11. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A, Ferrari M, Schleifer G, Cooper MK, Liu C, Yu B, Berra L, Klings ES, Safo RS, Chen Q, Musayev FN, Safo MK, Abdulmalik O, Bloch DB, Zapol WM.
    Mol Pharm; 2018 May 07; 15(5):1954-1963. PubMed ID: 29634905
    [Abstract] [Full Text] [Related]

  • 12. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM, Mahran MA, Ghatge MS, Chowdhury N, Bamane FH, El-Araby ME, Abdulmalik O, Safo MK.
    Org Biomol Chem; 2015 Jun 14; 13(22):6353-70. PubMed ID: 25974708
    [Abstract] [Full Text] [Related]

  • 13. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
    Huang B, Ghatge MS, Donkor AK, Musayev FN, Deshpande TM, Al-Awadh M, Alhashimi RT, Zhu H, Omar AM, Telen MJ, Zhang Y, McMahon TJ, Abdulmalik O, Safo MK.
    Molecules; 2022 Oct 12; 27(20):. PubMed ID: 36296435
    [Abstract] [Full Text] [Related]

  • 14. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM, Pagare PP, Ghatge MS, Chen Q, Musayev FN, Venitz J, Zhang Y, Abdulmalik O, Safo MK.
    Acta Crystallogr D Struct Biol; 2018 Oct 01; 74(Pt 10):956-964. PubMed ID: 30289405
    [Abstract] [Full Text] [Related]

  • 15. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA.
    Blood; 2021 Sep 30; 138(13):1172-1181. PubMed ID: 34197597
    [Abstract] [Full Text] [Related]

  • 16. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR.
    Br J Haematol; 2016 Oct 30; 175(1):141-53. PubMed ID: 27378309
    [Abstract] [Full Text] [Related]

  • 17. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
    Schroeder P, Fulzele K, Forsyth S, Ribadeneira MD, Guichard S, Wilker E, Marshall CG, Drake A, Fessler R, Konstantinidis DG, Seu KG, Kalfa TA.
    J Pharmacol Exp Ther; 2022 Mar 30; 380(3):210-219. PubMed ID: 35031585
    [Abstract] [Full Text] [Related]

  • 18. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M, Sturtevant S, Guertin KR, Gupta D, Desai K, Vieira BF, Li W, Hicks A, Ismail A, Gonçalves BP, Di Caprio G, Schonbrun E, Hansen S, Musayev FN, Safo MK, Wood DK, Higgins JM, Light DR.
    Blood Adv; 2021 Mar 09; 5(5):1388-1402. PubMed ID: 33661300
    [Abstract] [Full Text] [Related]

  • 19. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB, Liang H, Meng F, Harper J, Ostrowski DA, Henry ER, Shet AS, Eaton WA, Thein SL, Alayash AI.
    Bioconjug Chem; 2019 Mar 20; 30(3):568-571. PubMed ID: 30794381
    [Abstract] [Full Text] [Related]

  • 20. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T, Strader MB, Nakagawa A, Zapol WM, Alayash AI.
    Metallomics; 2017 Sep 20; 9(9):1260-1270. PubMed ID: 28770911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.